1.Pollack, C.V. et al. Final Results of RE-VERSE AD Study: Reversal of Dabigatran by its Specific Reversal Agent Idarucizumab in Patients with Uncontrolled Bleeding or Requiring Urgent Surgery/Procedures. International Society on Thrombosis and Haemostasis (ISTH) 26th Biennial Congress and 63rd Annual Scientific and Standardization Committee (SSC), Berlin, July 2017, Late-breaking abstract 01.4.
2.Pollack, C.V. et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. New Engl J Med. 2017; DOI: 10.1056/NEJMoa1707278. www.nejm.org/doi/full/10.1056/NEJMoa1707278
3.Idarucizumab European Summary of Product Characteristics, 2016.
4.Idarucizumab US Prescribing Information 2015.
5.https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-launches-re-vecto-global-program
6.Pollack C.V. et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114 (1) :198-205.
7.Schiele, F. et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121 (18) :3554-62.
8.Boehringer Ingelheim. Data on File.
9.Pradaxa® US Prescribing Information, 2015.
10.Pradaxa® European Summary of Product Characteristics, 2016.
11.Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47 (5) :285–95.
12.Di Nisio, M. et al. Direct thrombin inhibitors. N Engl J Med.2005;353:1028–40.
13.Stangier, J. et al. Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement. J Clin Pharmacol. 2005;45:555–63.